OnCo
Cancers & treatments·Sequencing

Myelodysplastic syndromes / neoplasms (MDS): lines of therapy

Cancer page →

4 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Special situations1
Other settings3

Special situations

SubgroupSettingApproachProducts and trialsEvidence
All comersSupportive care, all risksTransfusion, iron chelation for transfusional iron overload (TELESTO), infection management, G-CSF for neutropenic infection.
Transfusion support and anaemia managementGrowth factors: G-CSF and febrile neutropenia prevention
71

Other settings

SubgroupSettingApproachProducts and trialsEvidence
All comersLower risk, anaemiaESA if serum EPO <500; luspatercept first line (COMMANDS) or after ESA failure (MEDALIST); imetelstat after ESA failure (IMerge); lenalidomide for del(5q).
LuspaterceptImetelstatLenalidomide
87
All comersHigher risk, transplant candidateAllogeneic HSCT, usually after hypomethylating-agent cytoreduction; BMT CTN 1102 showed a survival benefit for transplant in 50-75-year-olds.
Allogeneic stem cell transplantationAzacitidine
89
All comersHigher risk, not transplant candidateAzacitidine (AZA-001) or decitabine / oral decitabine-cedazuridine until progression; supportive care and trials.
AzacitidineDecitabine + cedazuridine (oral)
89

Regimens in the library

Venetoclax + azacitidine

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.